Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome

• Published in: Nutrients 2017-11, Vol.9 (12), p.1280
• Main Authors: Jamilian, Mehri, Foroozanfard, Fatemeh, Rahmani, Elham, Talebi, Maesoomeh, Bahmani, Fereshteh, Asemi, Zatollah
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Androgens - blood; Anthropometry; Antioxidants; Biomarkers - blood; Blood Glucose - metabolism; C-reactive protein; C-Reactive Protein - metabolism; Diet; Dietary Carbohydrates - administration & dosage; Dietary Fats - administration & dosage; Dietary Fiber - administration & dosage; Dietary Proteins - administration & dosage; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Female; Globulins; Hirsutism; hormonal profiles; Humans; Insulin; Insulin Resistance; insulin-resistant; Metabolism; Metabolome; Nutrition Assessment; Oxidative Stress - drug effects; Polycystic ovary syndrome; Polycystic Ovary Syndrome - blood; Polycystic Ovary Syndrome - drug therapy; Sex Hormone-Binding Globulin - metabolism; Testosterone; Testosterone - blood; Vitamin D; Vitamin D - administration & dosage; Vitamin D - blood; vitamin D supplementation; Young Adult
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu9121280

This study was carried out to evaluate the effects of vitamin D supplementation on the metabolic profiles of insulin-resistant subjects with polycystic ovary syndrome (PCOS). This randomized double-blind, placebo-controlled trial was conducted on 90 insulin-resistant women with PCOS. Participants were randomly assigned to three groups to intake either 4000 IU of vitamin D or 1000 IU of vitamin D or placebo ( = 30 each group) daily for 12 weeks. Vitamin D supplementation (4000 IU), compared with vitamin D (1000 IU) and placebo, led to significant reductions in total testosterone (-0.2 ± 0.2 vs. -0.1 ± 0.6 and +0.1 ± 0.2 ng/mL, respectively, = 0.02), free androgen index (FAI) (-0.06 ± 0.12 vs. -0.02 ± 0.12 and +0.004 ± 0.04, respectively, = 0.04), hirsutism (-1.1 ± 1.1 vs. -0.8 ± 1.2 and -0.1 ± 0.4, respectively, = 0.001) and high-sensitivity C-reactive protein (hs-CRP) (-0.7 ± 1.4 vs. -0.5 ± 0.9 and +0.5 ± 2.4 mg/L, respectively, = 0.01). In addition, we found significant elevations in mean change of sex hormone-binding globulin (SHBG) (+19.1 ± 23.0 vs. +4.5 ± 11.0 and +0.7 ± 10.4 nmol/L, respectively, < 0.001) and total antioxidant capacity (TAC) (+130 ± 144 vs. +33 ± 126 and -36 ± 104 mmol/L, respectively, < 0.001) in the high-dose vitamin D group compared with low-dose vitamin D and placebo groups. Overall, high-dose vitamin D administration for 12 weeks to insulin-resistant women with PCOS had beneficial effects on total testosterone, SHBG, FAI, serum hs-CRP and plasma TAC levels compared with low-dose vitamin D and placebo groups.